Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0130

PERSPECTIVE
Comparative-effectiveness research and personalized medicine: Trends and debate

Prof. Theodore Liakakos, MD, PhD

Affiliation: Theodore Liakakos, MD, Professor of Surgery, 3rd Department of Surgery, University of Athens, School of Medicine, Attikon University Hospital, Rimini 1, Chaidari, Athens 12462, Greece.

E-mail: theodlia@otenet.gr

ABSTRACT

Comparative-effectiveness research (CER) is the current gold standard for improving health care. New products including drugs, medical devices, diagnostics, biomarkers and therapeutics should be proven more effective and safe as compared to standards that are used in a day-to-day clinical practice. International and national Organizations or Agency, such as FDA require rigorous criteria for approval of new diagnostics and therapeutics usually met in large randomized controlled trials. However, such an evaluation does not consider differences in therapy response and adverse effects among patients with same disease who receive the same treatment.

Based on the recent DNA sequencing technology explosion that reveals a widespread genetic variation among patients, a similar explosion over the last few years has been occurred on research for personalized medicine. Aim is to discover those causal mutations characteristic for each patient, which will allow the development of specific individualized therapies. However, there is critique that it is too early for personalized diagnostics and therapeutic approaches and this human genome heterogeneity-based research requires major costs and funding with uncertain effectiveness.

This perspective article discusses strengthens and weaknesses of CER and personalized medicine for improving health care. It is particularly considered costs, funding priorities by agencies and potential harms for the population when very expensive new targeted therapies, for example in cancer treatment, are promoted by industry in the pharmaceutical market with uncertain effectiveness and safety.

http://www.gastricbreastcancer.com/grade_yachtmaster.asp

http://www.gastricbreastcancer.com/grade_deville.asp

(Citation: Gastric & Breast Cancer 2010; 9(3): 95-101)
You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 26 April 2010